Latest news with #CAH
Yahoo
02-06-2025
- General
- Yahoo
Carthage Area Hospital honors Nurse Jennifer Putnam with DAISY Award
CARTHAGE, N.Y. (WWTI) – Carthage Area Hospital (CAH), part of the North Star Health Alliance (NSHA), announces that Jennifer Putnam, RN, has received The DAISY Award® for her outstanding patient care. CAH says her compassion during vulnerable moments showcases the essence of nursing. Putnam's commitment reminds the hospital of the significant impact one nurse can have, and the hospital says they are proud to honor her within the North Star Health Alliance. Traffic Alert: Intersection of Stone Street & Sherman Street in Watertown 8 injured in Pearl Street Mall attack; Law enforcement ID suspect Mets take home win in Sunday finale against Iowa Carthage Area Hospital honors Nurse Jennifer Putnam with DAISY Award West Genesee takes home second straight Class AA championship 'My favorite person in the whole world was my grandmother. When she was near the end of her battle with cancer, a nurse would sing to her each day—bringing her peace and taking away her fear, even if just for five minutes. I knew then that if someone could do that for another person, I wanted to be a part of it,' Putnam shared, reflecting on what drew her to nursing. She said that moment cemented her calling and her first clinical rotation back at Carthage Hospital only deepened her love for patient care. Putnam is essential to the Carthage ER team, expertly guiding patients and families through critical moments with warmth and kindness. Her considerate support, unfailing generosity, and dedication to reducing pain and anxiety are prime examples of the exceptional care that The DAISY Award® honors, says CAH. 'Jennifer's compassion goes hand in hand with her clinical excellence. She has an uncanny ability to tune into what her patients need most—whether that's a medical intervention or simply someone to listen. By openly sharing her own stories, she builds bridges of trust and eases her patients' fears in their toughest moments. Her empathetic presence transforms the care experience, reminding everyone on our team of the profound impact kindness and genuine connection can have on healing.' David Ferris, MSHA, RN, FACHE, Chief Nursing Officer, Senior Vice President of Patient Care The North Star Health Alliance and Carthage Area Hospital congratulated Putnam on this earned accolade. CAH praised her unwavering dedication to patient-centered care. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
15-05-2025
- Business
- Yahoo
CAH Q1 Earnings Call: Cardinal Health Misses Revenue Targets but Exceeds Profit Expectations Amid Tariff Headwinds
Healthcare distributor and services company Cardinal Health (NYSE:CAH) fell short of the market's revenue expectations in Q1 CY2025, with sales flat year on year at $54.88 billion. Its non-GAAP profit of $2.35 per share was 9.4% above analysts' consensus estimates. Is now the time to buy CAH? Find out in our full research report (it's free). Revenue: $54.88 billion vs analyst estimates of $55.46 billion (flat year on year, 1% miss) Adjusted EPS: $2.35 vs analyst estimates of $2.15 (9.4% beat) Adjusted EBITDA: $849 million vs analyst estimates of $876.8 million (1.5% margin, 3.2% miss) Adjusted EPS guidance for the full year is $8.10 at the midpoint, beating analyst estimates by 1.7% Operating Margin: 1.3%, in line with the same quarter last year Free Cash Flow was $2.79 billion, up from -$161 million in the same quarter last year Market Capitalization: $35.42 billion Cardinal Health's Q1 results reflected a business in transition, as revenue came in just below Wall Street expectations while non-GAAP profit surpassed analyst forecasts. Management pointed to continued growth across its Pharmaceutical and Specialty Solutions segment, contributions from recent acquisitions, and operational improvements in its Global Medical Products and Distribution (GMPD) business as key performance drivers. The company also highlighted progress in onboarding new customers and expanding higher-margin services, which offset some external headwinds. Looking ahead, Cardinal Health raised its non-GAAP EPS guidance for the year, citing strong demand for specialty pharmaceuticals, growth in at-Home Solutions, and early benefits from the integration of Advanced Diabetes Supply Group. Management noted ongoing cost control efforts and investments in U.S. manufacturing and automation, but remained cautious about tariff-related risks and the impact of regulatory changes. CEO Jason Hollar emphasized that, 'the largest and highest growth parts of our business are resilient and well positioned to continue growth,' while acknowledging the company's focus on mitigating the financial impact of tariffs in GMPD. Management attributed the quarter's performance to resilient pharmaceutical demand, effective cost control, and growth in targeted business areas. The company's ability to manage through supply chain challenges and tariffs, while integrating new acquisitions, was a recurring theme. Specialty segment momentum: Growth in specialty pharmaceuticals and new customer onboarding, including the successful addition of Publix, drove segment profit. Specialty now represents a growing portion of the overall business mix, aided by acquisitions of GI Alliance and Integrated Oncology Network. GMPD turnaround progress: The GMPD segment saw improved profitability from operational efficiencies and cost reduction initiatives, with Cardinal Health branded products showing above-average growth compared to national brands. Tariff mitigation strategies: Management discussed aggressive steps to reduce tariff exposure, including expanding U.S. manufacturing, diversifying supply chains, leveraging tariff exemptions (such as the Nairobi protocol), and using artificial intelligence for compliance and planning. Most tariff costs in GMPD are expected to be addressed through operational actions and selective price adjustments. Integration of acquisitions: The company reported early positive contributions from GI Alliance, Integrated Oncology Network, and the Advanced Diabetes Supply Group, particularly in expanding higher-margin revenue streams and specialty care capabilities. Growth in high-margin segments: Other growth businesses, including At-Home Solutions, Nuclear, and OptiFreight, delivered double-digit profit growth. Management highlighted secular trends such as increased outpatient care and the demand for nuclear medicine as supportive of future performance. Cardinal Health's management anticipates continued earnings growth driven by demand for specialty pharmaceuticals, ongoing cost discipline, and successful integration of recent acquisitions, but flagged tariffs and regulatory actions as areas of uncertainty. Specialty and biologics expansion: The company expects further growth in specialty pharmaceutical distribution, including both upstream (manufacturer partnerships) and downstream (services to physician practices) businesses, bolstered by recent acquisitions. Tariff exposure and mitigation: While most business lines are not significantly impacted by tariffs, GMPD remains exposed. Management aims to offset the majority of gross tariff costs through cost-cutting and price adjustments, but some uncertainty remains regarding regulatory changes and the final financial burden. Operational investments: Strategic investments in automation, technology, and U.S.-based manufacturing are intended to improve efficiency and support long-term growth, while integration of new businesses (such as Advanced Diabetes Supply Group) is expected to enhance profitability and expand the service portfolio. Lisa Gill (JPMorgan): Asked about sustainability of specialty and branded sales growth; management pointed to broad-based demand and consistent growth across product lines, noting that recent customer wins are expected to support ongoing momentum. Allen Lutz (Bank of America): Questioned whether tariffs or macroeconomic weakness were affecting prescription volumes; CEO Jason Hollar replied that pharmaceutical demand remains resilient even during broader economic downturns, citing historical trends. Joanna Dynak (Evercore ISI): Requested details on Cardinal Health branded GMPD revenue and tariff recovery; management declined to share profit mix specifics but noted strong branded product growth and ongoing use of tariff exemptions. Eric Percher (Nephron): Sought clarification on how much of the $200–$300 million in GMPD tariff costs could be offset by pricing; management expects the majority to be addressed through price increases, especially on Cardinal Health branded products. Daniel Grosslight (Citi): Asked about the practical ability to pass on price increases given customer contracts; management said most price adjustments would follow operational mitigation, and efforts would focus on collaboration with customers to avoid supply disruptions. Looking ahead, the StockStory team will monitor (1) Cardinal Health's ability to sustain specialty pharmaceutical growth and integrate new customer wins, (2) the effectiveness of tariff mitigation strategies within GMPD, and (3) progress in expanding higher-margin businesses such as At-Home Solutions and Nuclear. Updates at the upcoming Investor Day and further color on regulatory or tariff actions will also be important indicators of future performance. Cardinal Health currently trades at a forward P/E ratio of 17×. Is the company at an inflection point that warrants a buy or sell? See for yourself in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
Yahoo
09-05-2025
- Business
- Yahoo
Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ...
Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) is strategically positioned for long-term sustainable growth with a focus on the anticipated commercial launch of their first products this year. The company has a robust pipeline, including two late-stage candidates and three additional candidates in pre-clinical studies. Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) has a strong financial position with $1.3 billion on the balance sheet, allowing continued investment in their pipeline and support for prospective launches. The anticipated launch of Paltustine for acromegaly is a pivotal milestone, with positive feedback from healthcare professionals and strong patient advocacy partnerships. Regulatory engagement with the FDA and European Medicines Agency is proceeding on track, with no disruptions anticipated for the Paltustine NDA review. Research and development expenses increased by 43% compared to the same period in 2024, primarily due to additional personnel and increased manufacturing costs. Selling, general, and administrative expenses rose by 71% compared to the same period in 2024, driven by growth to support ongoing programs and the planned commercial launch. Cash used in operations increased significantly, with expectations for cash use in operations to be between $340 and $380 million for 2025. The company anticipates a measured uptake of Paltustine during early launch, with coverage expected to build progressively over the first 6 to 9 months. There is a significant unmet need for safe, highly efficacious, easy-to-administer treatments, indicating challenges in meeting current market demands. Warning! GuruFocus has detected 3 Warning Signs with CRNX. Q: Could you talk about the power of your innovative primary endpoint, which is a co-primary, and have you been able to collect any data from cohort 4 yet? A: The study is highly powered to detect statistically significant differences between the treatment and placebo arms. Cohort 4 is enrolling, but we can't comment on the timing of data yet. The primary endpoint is better described as a composite endpoint rather than a co-primary endpoint. It involves a responder analysis where a responder is defined as having both normal glucocorticoid doses and normal A4 levels. - Dr. Alan Krasner, Chief Endocrinologist Q: Is the CAH study design fully signed off on by the FDA as a trial that could support registration, and what indication statement would you hope to secure assuming the trial is successful? A: The protocol was developed with input from the FDA and other health authorities, and they are aware of the final study design. We aim to develop a drug that treats CAH, requiring glucocorticoids only for adrenal insufficiency prevention. The indication might differ slightly from existing ones, as our drug aims to drive androgen reduction without needing glucocorticoids for that purpose. - Dr. Dana Pezzutti, Chief Medical and Development Officer Q: What's the rationale for testing the primary endpoint at a single point in time at 32 weeks instead of averaging across multiple time points? A: Responder analyses are typically conducted at single points in time. While there's always variability with biochemical markers, A4 is one of the least variable in this disease state. The compound is expected to achieve both components of the composite primary endpoint, minimizing the risk of variability affecting results. - Dr. Alan Krasner, Chief Endocrinologist Q: What is the rationale for looking at morning dosing versus evening dosing in the fourth cohort? A: Morning dosing might be more convenient for patients, and we want to explore this option to provide future flexibility. The timing of the drug in relation to the diurnal rhythm of the axis, including in CAH patients, is important to ensure it doesn't have a significant effect. - Dr. Scott Struthers, CEO Q: How are you thinking about launch strategy in different geographies, especially in Europe and Latin America? A: In Europe, patient concentration is even more at centers of excellence compared to the US. We are preparing for a launch in Germany and have a small team in place. In Latin America, Brazil is a key market due to its high unmet need and concentrated patient population. We plan to expand gradually and thoughtfully. - Isabel Califanos, Chief Commercial Officer For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Time of India
09-05-2025
- Science
- Time of India
How do archaeologists determine the gender of a skeleton?
Credit: Canva When archaeologists come across ancient human skeletons, one of the first things they try to do is figure out the gender of the skeleton, whether it was male or female. While it might sound straightforward, the process is neither simple nor it's always accurate. "Overall, we're looking at shape and size differences between the sexes," said Sean Tallman, a biological anthropologist at Boston University, in an interview with Live Science. However, he added, "no one method is 100% accurate." Measuring bones One common way to estimate sex is by measuring long bones, like the femur and tibia. These bones are generally larger in males. 'On average, males are about 15% larger than females,' said Kaleigh Best, a biological anthropologist at Western Carolina University, in an interview with Live Science. Operation Sindoor 'Did not want to...': Pak def min gives absurd excuse for army's failure to withstand Op Sindoor Blackouts, sirens & Pak's failed attacks: 10 things that happened in the last 36 hrs '1971 war was not remotely as terrifying': Residents of border areas shell-shocked But factors like diet, health, and genetics can all affect bone size, which makes this method only about 80% to 90% accurate. The Phenice method This technique looks at specific features of the pubic bone. A taller and narrower pubic bone often means that it belongs to a male, while a wider one usually indicates a female. With this method, it is assumed that a trained expert can predict the sex of a skeleton with about 95% accuracy. DNA testing By analyzing ancient DNA, scientists can often figure out the chromosomal sex with up to 99% accuracy. The process involves identifying genes linked to sex chromosomes. However, it is hardly unlikely that DNA would survive over long periods, especially in harsh conditions. So it might not always be an option. Even with these advanced techniques, some skeletons defy simple classification. "Sex is not binary, but it may be bimodal," said Donovan Adams, a biological anthropologist at the University of Central Florida. This means there are two main patterns — male and female — but also a significant number of people who fall somewhere in between. Credit: Canva Experts say that about 1.7% of people are born intersex — a term for individuals with a mix of male and female biological traits. That's about 1 in 50 people. Intersex conditions can include things like XXY chromosomes (Klinefelter syndrome) or conditions like CAH (congenital adrenal hyperplasia), which can make female genitalia appear male at birth. Virginia Estabrook, a biological anthropologist at the University of Maryland, Baltimore County, explained to Live Science how she studied the skeleton of Revolutionary War hero Casimir Pulaski, whose bones appeared female, even though records show he lived as a man. One explanation could be CAH. Understanding identity from bones alone is tricky. Bones can reflect lifestyle habits that may be linked to gender roles, like archery or grinding grain, but that doesn't always line up with biological sex or personal identity. While with new tech, determining the gender of a skeleton has become more accurate, we still have a long way to go.
Irish Independent
07-05-2025
- Automotive
- Irish Independent
Community rallies to help young Leitrim boy (8) with rare disorder pursue his farming dream
Michael Barry (8) is the son of Cllr Brendan Barry and Nicola and a brother to Shauna. The family live In Drumshanbo, Co Leitrim. Michael was born with a very rare condition: Genetic deletion Contiguous XP21 deletion syndrome. The condition leads to the co-occurrence of several related genetic disorders, including Duchenne muscular dystrophy (DMD), congenital adrenal hypoplasia (CAH), and glycerol kinase deficiency (GKD). Duchenne muscular dystrophy is a terminal muscle wasting condition which causes a progressive loss of muscle in every organ and part of the body and usually impacts boys. Michael has never walked unaided and is a wheelchair user. Despite his challenges, the young man has a love of farming and spending his days on the land and watching the cows. However, the family farm is not accessible by car. To combat this, a GoFundMe page has been launched to purchase an all terrain vehicle, such as a quad, with an enclosed cab. The vehicle would allow Michael to roam to fields and yard safely. The vehicle will cost approximately between €15,000 and €20,000. So far, almost €25,000 has been raised by the fundraiser. The fund has been further bolstered as a local family donated money towards helping Michael in memory of their son and brother Ronan Moran, who was friends with Michael. Last year, €2,000 was raised for Michael in conjunction with Allen Gaels GAA who were raising funds for local groups and people with the inaugural 'Shroomsday event'. The Barry family are incredibly grateful for the support and donations they have received from the local community. The GoFundMe page explains, 'Michael is a typical boy when it comes to wanting to be out and about and on the farm. 'It is not possible to get a car around our farm. In the vehicle, he would have his own seat and be strapped in while being protected from the elements. 'With €2,000 being donated to Michael from the Shroomsday event, Allen Gaels have again offered to donate funds from a 25 card drive to Michael. 'We plan to spend this on the purchase of an all terrain vehicle like a quad with enclosed cab which would be much safer and drier for Michael to be able to go farming and see the cows. 'It will cost approximately between €15,000 and €20,000. 'We are setting up this go fund me if others would like to help with this purchase or other things to help Michael enjoy life to his full potential,' reads the fundraiser. To donate to the fundraiser, visit the GoFundMe page here.
